Pablo D. Hendler, Partner with Jones Day to Speak at The Knowledge Group’s Tips and Strategies in Winning Paragraph IV Disputes in 2016 & Beyond

New York, NY, May 26, 2016 --(PR.com)-- The Knowledge Group/The Knowledge Congress Live Webcast Series, the leading producer of regulatory focused webcasts, has announced today that Pablo D. Hendler, Partner with Jones Day will speak at the Knowledge Group’s webcast entitled: “Tips and Strategies in Winning Paragraph IV Disputes in 2016 & Beyond.” This event is scheduled for August 23, 2016 from 12:00pm to 2:00pm (ET).

For further details, please visit: https://theknowledgegroup.org/event-homepage/?event_id=1963

About Pablo D. Hendler

Pablo Hendler recently joined Jones Day bringing with him extensive experience in all aspects of litigation, involving a broad range of technologies, particularly life science patent litigation. He has a unique combination of skills as a research chemical engineer, inventor, and attorney with more than 20 years of experience in patent infringement litigation, of which more than 15 years is primarily focused on pharmaceutical (e.g., Hatch-Waxman), biotechnology, and medical device litigation. Pablo's litigation experience includes serving as lead counsel and ranges from prediscovery diligence to preliminary injunction proceedings, trial, and appeals involving patents, false advertising, trademark, trade secret misappropriation, and breach of contract.

Pablo has successfully represented clients in numerous pharmaceutical patent cases involving: ANDAs (abbreviated new drug applications) concerning inhalation medication for the treatment of asthma, improved oxycodene formulations, controlled release opioid analgesics, antifungul agents, and a niacin cholesterol-lowering drug; genetically modified mice; plasmid vectors; nutraceuticals; and autonomous medical imaging, infusion pumps, spinal fusion implants, corn herbicides, purge and trap concentrators for gas chromatography, and machine vision and bar code technologies.

About Jones Day

Jones Day is a global law firm with 43 offices in major centers of business and finance throughout the world. Its unique governance system fosters an unparalleled level of integration and contributes to its perennial ranking as among the best in the world in client service. Jones Day provides significant legal representation for almost half of the Fortune 500, Fortune Global 500, and FT Global 500.

Abstract

Under Hatch-Waxman Act, a generic challenger seeking abbreviated new drug application (ANDA) approval is required to file a certification regarding each relevant Orange Book patent. One of the certifications an ANDA applicant may file is the Paragraph IV certification which states that the branded drug’s “patent is invalid, unenforceable or would not be infringed by marketing of the ANDA product.” Considered as a technical act of patent infringement, a Paragraph IV filing gives the brand pharmaceutical company the right to initiate a patent infringement lawsuit. With the increasing number of Paragraph IV filings and the vulnerability of every product as a generic target, both generic and brand companies should therefore expect Paragraph IV litigation and be prepared with its coming. In this two-hour Live Webcast, a panel of distinguished professionals and thought leaders assembled by The Knowledge Group will help generic and brand pharmaceutical companies understand the fundamental as well as complex aspects of this significant topic. They will also offer best tips and strategies in winning Paragraph IV Disputes.

About The Knowledge Group/The Knowledge Congress Live Webcast Series

The Knowledge Group was established with the mission to produce unbiased, objective, and educational live webinars that examine industry trends and regulatory changes from a variety of different perspectives. The goal is to deliver a unique multilevel analysis of an important issue affecting business in a highly focused format. To contact or register for an event, please visit: http://theknowledgegroup.org /